PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load
NCT ID: NCT02158221
Last Updated: 2015-02-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
32 participants
INTERVENTIONAL
2014-06-30
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CGRP Induced Migraine Attacks in Patients With High and Low Genetic Load
NCT01924052
PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow
NCT00380263
Hypersensitivity to PACAP-38 in Post-Traumatic Headache
NCT05378061
Transcriptomic and Biochemical Changes During a Migraine Attack
NCT02468622
PACAP-38 Infusion in Patients With Cluster Headache
NCT03814226
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PACAP is a neuropeptide which plays a crucial role in the pathophysiology of migraine and is present in migraine relevant structures. PACAP can induce migraine attacks in MO patients via an adenosine monophosphate (cAMP) dependent pathway. Also, a recent study has showed that intracellular accumulation of cAMP is crucial for the induction of migraine attacks.
The phenotype of the migraine inducing effects of PACAP might therefore be linked to some of the 12 genetic susceptibility loci that have been identified.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Migraine patients with high genetic load
PACAP intravenous infusion 1.5 microgram/min for 20 min
PACAP
Pituitary adenylate cyclase-activating polypeptide (PACAP)
Migraine patients with low genetic load
PACAP intravenous infusion 1.5 microgram/min for 20 min
PACAP
Pituitary adenylate cyclase-activating polypeptide (PACAP)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PACAP
Pituitary adenylate cyclase-activating polypeptide (PACAP)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* A history of cerebrovascular disease and other CNS- disease
* A history suggesting ischaemic heart disease
* Serious somatic and mental disease
* Hypo- or hypertension
* Abuse of alcohol or medicine (opioid analgesics).
* Pregnant or breastfeeding women.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Danish Headache Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Song Guo
MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Danish Headache Center & Department of Neurology
Copenhagen, Glostrup, Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-2-2013-043
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.